Modeling Niemann-Pick disease type C1 in zebrafish: a robust platform for in vivo screening of candidate therapeutic compounds
Authors:
- Wei-Chia TsengWTWei-Chia Tseng
- Chon-Hwa Tsai-MorrisCTChon-Hwa Tsai-Morris
- Lisha XuLXLisha Xu
- Celine V. CluzeauCCCeline V. Cluzeau
- Christopher A. WassifChristopher A. Wassif
- Benjamin FeldmanBFBenjamin Feldman
- Shawn M. BurgessShawn M. Burgess
- William J. PavanWPWilliam J. Pavan
- Forbes D. PorterFPForbes D. Porter
Open Access
- 15 August 2018
- journal article
- research article
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 11 (9)
Abstract
Niemann-Pick disease type C1 (NPC1) is a rare autosomal recessive lysosomal storage disease primarily caused by mutations in NPC1. NPC1 is characterized by abnormal accumulation of unesterified cholesterol and glycolipids in late endosomes and lysosomes. Common signs include neonatal jaundice, hepatosplenomegaly, cerebellar ataxia, seizures and cognitive decline. Both mouse and feline models of NPC1 mimic the disease progression in humans and have been used in preclinical studies of 2-hydroxypropyl-β-cyclodextrin (2HPβCD; VTS-270), a drug that appeared to slow neurological progression in a Phase 1/2 clinical trial. However, there remains a need to identify additional therapeutic agents. High-throughput drug screens have been useful in identifying potential therapeutic compounds; however, current preclinical testing is time and labor intensive. Thus, development of a high-capacity in vivo platform suitable for screening candidate drugs/compounds would be valuable for compound optimization and prioritizing subsequent in vivo testing. Here, we generated and characterize two zebrafish npc1-null mutants using CRISPR/Cas9-mediated gene targeting. The npc1 mutants model both the early liver and later neurological disease phenotypes of NPC1. LysoTracker staining of npc1 mutant larvae was notable for intense staining of lateral line neuromasts, thus providing a robust in vivo screen for lysosomal storage. As a proof of principle, we were able to show that treatment of the npc1 mutant larvae with 2HPβCD significantly reduced neuromast LysoTracker staining. These data demonstrate the potential value of using this zebrafish NPC1 model for efficient and rapid in vivo optimization and screening of potential therapeutic compounds. This article has an associated First Person interview with the first author of the paper.Keywords
Funding Information
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (ZIA HD000139)
- National Human Genome Research Institute
This publication has 55 references indexed in Scilit:
- Disease and patient characteristics in NP-C patients: findings from an international disease registryOrphanet Journal of Rare Diseases, 2013
- A novel mouse model of Niemann–Pick type C disease carrying a D1005G-Npc1 mutation comparable to commonly observed human mutationsHuman Molecular Genetics, 2011
- Requirement of Npc1 and availability of cholesterol for early embryonic cell movements in zebrafishJournal of Lipid Research, 2011
- Zebrafish model of tuberous sclerosis complex reveals cell-autonomous and non-cell-autonomous functions of mutant tuberinDisease Models & Mechanisms, 2011
- Weekly Cyclodextrin Administration Normalizes Cholesterol Metabolism in Nearly Every Organ of the Niemann-Pick Type C1 Mouse and Markedly Prolongs LifePediatric Research, 2010
- Niemann-Pick disease type COrphanet Journal of Rare Diseases, 2010
- Chemical screen to reduce sterol accumulation in Niemann–Pick C disease cells identifies novel lysosomal acid lipase inhibitorsBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2009
- Chronic Cyclodextrin Treatment of Murine Niemann-Pick C Disease Ameliorates Neuronal Cholesterol and Glycosphingolipid Storage and Disease ProgressionPLOS ONE, 2009
- Structure of N-Terminal Domain of NPC1 Reveals Distinct Subdomains for Binding and Transfer of CholesterolCell, 2009
- Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1 −/− mouseProceedings of the National Academy of Sciences, 2009